Regeneron Pharmaceuticals, Inc. (REGN)
|52 Week Range||538.01-837.55|
|1y Target Est||-|
|DCF Unlevered||REGN DCF ->|
|DCF Levered||REGN LDCF ->|
|Debt / Equity||27.94%||Neutral|
Upgrades & Downgrades
Latest REGN news
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
26 May 2023
A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
Regeneron (REGN) Faces Challenges as Eylea Sales Decline
19 May 2023
Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.
Regeneron Announces Investor Conference Presentations
18 May 2023
TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
The 7 Growth Stocks You Need to Own Now for Maximum Returns
17 May 2023
Although recent headwinds like stubbornly high inflation and the banking sector crisis knocked the wind out of several publicly traded enterprises, a select number of hardened survivors potentially re...
Regeneron Pharmaceuticals, Inc. (REGN) Bank of America Global Healthcare Conference Call Transcript
13 May 2023
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Bank of America Global Healthcare Conference Call May 9, 2023 4:40 PM ET Company Participants Ryan Crowe - VP, IR Robert Landry - EVP, Finance & CFO Conf...
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
5 May 2023
Regeneron Pharmaceuticals Inc. NASDAQ: REGN gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.
Why Regeneron Pharmaceuticals Stock Is Tanking Today
4 May 2023
Regeneron Pharmaceuticals posted overall positive 2023 Q1 results today. Even so, investors are concerned about the competitive positioning of the drugmaker's blockbuster eye-care treatment.
Regeneron (REGN) Q1 Earnings and Revenues Top Estimates
4 May 2023
Regeneron (REGN) came out with quarterly earnings of $10.09 per share, beating the Zacks Consensus Estimate of $9.25 per share. This compares to earnings of $11.49 per share a year ago.
Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker
4 May 2023
Regeneron Pharmaceuticals beat first-quarter sales and profit calls, but Eylea revenue came up short and REGN stock tumbled. The post Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneym...
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >